Childhood Cancers Subject of New Law

Publication
Article
OncologyONCOLOGY Vol 14 No 12
Volume 14
Issue 12

At the end of its session, Congress passed a children’s health bill (H.R. 4365) that established a variety of new health programs. One section of the bill authorizes the CDC to study environmental and other risk factors for childhood cancers,

At the end of its session, Congress passed a children’shealth bill (H.R. 4365) that established a variety of new health programs. Onesection of the bill authorizes the CDC to study environmental and other riskfactors for childhood cancers, including skeletal malignancies, leukemias,malignant tumors of the central nervous system, lymphomas, soft-tissue sarcomas,and other malignant neoplasms. In addition to studying those conditions, the CDCwas told to fund projects to improve outcomes among children with those cancersand resulting secondary conditions, such as loss of limbs. The CDC already has aprogram to help states set up cancer registries. The states themselves decidewhat the registries will focus on, and some of them are very narrowly gauged.Thirty-nine states have registries. The CDC gave away $24 million in fiscal year2000 to these state registries. Very few of the states do much with regard tochildhood cancers, and the CDC will ostensibly try to change this. Thejust-passed bill instructs the CDC to set up a national reporting system thatwill involve oncologists, who will have to provide diagnosis and epidemiolgicdata.

Recent Videos
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.